AR066095A1 - Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla - Google Patents
Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararlaInfo
- Publication number
- AR066095A1 AR066095A1 ARP080101584A ARP080101584A AR066095A1 AR 066095 A1 AR066095 A1 AR 066095A1 AR P080101584 A ARP080101584 A AR P080101584A AR P080101584 A ARP080101584 A AR P080101584A AR 066095 A1 AR066095 A1 AR 066095A1
- Authority
- AR
- Argentina
- Prior art keywords
- prepare
- halogen
- compound
- procedure
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Compuesto de oxadiazol de la formula (1) o sales del mismo: en la que uno de R5 y R6 es hidrogeno o R2 y el otro es formula (2), uno de R3 y R4 es formula (3); A es un fenilo o un anillo heteroarilo de 5 o 6 miembros; R1 es H o representa hasta tressustituyentes seleccionados independientemente entre halogeno, alquilo C1-4, alcoxi C1-4, cicloalquilo C5-7, cicloalcoxi C5-7, trifluorometoxi, difluorometoxi, trifluorometilo, ciano, fenilo, anillos heteroarilo de 5 o 6 miembros, piperidinilo ypirroIidiniIo; R2 es hidrogeno o representa hasta tres sustituyentes seleccionados independientemente entre halogeno, alquilo C1-4, alcoxi C1-4, trifluorometoxi, difluorometoxi, trifluorometilo, y ciano; R7 es H o halogeno; Z es alquilo C1-4 quepuede estar opcionalmente interrumpido una vez por N o O y que puede estar opcionalmente sustituido sobre C con hasta cuatro sustituyentes seleccionados independientemente entre halogeno, metilo e hidroxilo, con la condicion de que ningun átomo decarbono esté sustituido con dos grupos hidroxilo. Uso de dicho compuesto para preparar un medicamento par el tratamiento de enfermedades o trastornos mediados por los receptores S1P1, tal como esclerosis multiple. Composicion farmacéutica que locomprende y procedimiento para prepararla.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0707617A GB0707617D0 (en) | 2007-04-19 | 2007-04-19 | Compounds |
GB0805993A GB0805993D0 (en) | 2008-04-02 | 2008-04-02 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066095A1 true AR066095A1 (es) | 2009-07-22 |
Family
ID=39604751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080101584A AR066095A1 (es) | 2007-04-19 | 2008-04-17 | Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla |
Country Status (25)
Country | Link |
---|---|
US (1) | US8324254B2 (es) |
EP (1) | EP2137181B1 (es) |
JP (1) | JP5313229B2 (es) |
KR (1) | KR20090130062A (es) |
AR (1) | AR066095A1 (es) |
AT (1) | ATE500252T1 (es) |
AU (1) | AU2008240773B2 (es) |
BR (1) | BRPI0809472A2 (es) |
CA (1) | CA2684385A1 (es) |
CL (1) | CL2008001099A1 (es) |
CO (1) | CO6321136A2 (es) |
CR (1) | CR11119A (es) |
DE (1) | DE602008005285D1 (es) |
DO (1) | DOP2009000237A (es) |
EA (1) | EA016443B1 (es) |
HK (1) | HK1138001A1 (es) |
IL (1) | IL200870A (es) |
JO (1) | JO2686B1 (es) |
MA (1) | MA31311B1 (es) |
MX (1) | MX2009011155A (es) |
MY (1) | MY146606A (es) |
NZ (1) | NZ579595A (es) |
PE (1) | PE20090150A1 (es) |
TW (1) | TWI408137B (es) |
WO (1) | WO2008128951A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0709866B8 (pt) | 2006-04-03 | 2021-05-25 | Astellas Pharma Inc | compostos héteros e composição farmacêutica compreendendo ditos compostos |
JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
ATE531711T1 (de) * | 2007-12-18 | 2011-11-15 | Arena Pharm Inc | Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate |
CN101959883B (zh) * | 2008-04-04 | 2013-01-30 | 伊莱利利公司 | 3-吲唑基-4-吡啶基异噻唑类化合物 |
GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
KR20190004843A (ko) | 2008-07-23 | 2019-01-14 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[b]인돌-3-일)아세트산 유도체 |
NZ590328A (en) * | 2008-07-23 | 2013-04-26 | Novartis Ag | Sphingosine 1 phosphate receptor modulators and their use to treat polymyositis and dermatomyositis |
KR101660059B1 (ko) | 2008-08-22 | 2016-09-26 | 박스알타 인코퍼레이티드 | 중합체 벤질 카르보네이트-유도체 |
ES2583630T3 (es) | 2008-08-27 | 2016-09-21 | Arena Pharmaceuticals, Inc. | Derivados de ácido tricíclico sustituido como agonistas del receptor S1P1 útiles en el tratamiento de trastornos autoinmunes e inflamatorios |
US8536185B2 (en) | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
ES2543205T3 (es) * | 2008-12-18 | 2015-08-17 | Merck Serono S.A. | Derivados heteroácidos funcionales de oxidiazol |
GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
GB0910691D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
GB0910689D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
US8399451B2 (en) * | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
WO2011072488A1 (en) * | 2009-12-18 | 2011-06-23 | Glaxo Group Limited | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists |
CN103221391B (zh) | 2010-01-27 | 2018-07-06 | 艾尼纳制药公司 | (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法 |
CN105503882B (zh) | 2010-03-03 | 2019-07-05 | 艾尼纳制药公司 | 制备s1p1受体调节剂及其晶体形式的方法 |
CN104105687B (zh) * | 2012-02-03 | 2018-01-02 | 诺华股份有限公司 | 制备n‑(4‑环己基‑3‑三氟甲基‑苄氧基)‑乙亚氨酸乙酯的方法 |
JP2016028016A (ja) * | 2012-12-12 | 2016-02-25 | 大日本住友製薬株式会社 | オキサジアゾール誘導体とその医薬用途 |
JP6450315B2 (ja) * | 2013-08-20 | 2019-01-09 | Meiji Seikaファルマ株式会社 | S1p1受容体アゴニストの評価方法及びスクリーニング方法 |
MX2021011472A (es) | 2015-01-06 | 2022-08-17 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
MA47503A (fr) | 2017-02-16 | 2021-04-21 | Arena Pharm Inc | Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales |
CN109100971B (zh) * | 2018-08-20 | 2024-02-09 | 合肥华耀电子工业有限公司 | 一种带互锁功能的开关机时序控制电路 |
WO2020051378A1 (en) | 2018-09-06 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3939238A1 (de) * | 1989-11-28 | 1991-05-29 | Bayer Ag | Heterocyclisch substituierte acrylsaeureester |
DE4002466A1 (de) | 1990-01-28 | 1991-10-10 | Bayer Ag | Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester |
US5462943A (en) * | 1990-01-28 | 1995-10-31 | Bayer Aktiengesellschaft | Substituted acetic acid esters useful as pesticides per se and as intermediates for substitued acrylic esters pesticides |
US5262416A (en) * | 1990-01-28 | 1993-11-16 | Bayer Aktiengesellschaft | Pesticidal substituted 2-[6-(pyrimidinyl)-indol-1-yl]-acrylic esters |
US5523312A (en) * | 1994-09-27 | 1996-06-04 | Sterling Winthrop Inc. | Antipicornaviral agents |
JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
JP2001199983A (ja) * | 2000-01-18 | 2001-07-24 | Teijin Ltd | ベンズイミダゾール誘導体 |
EP1549640A4 (en) | 2002-06-17 | 2008-08-06 | Merck & Co Inc | 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS |
ES2392167T3 (es) * | 2003-04-30 | 2012-12-05 | Novartis Ag | Derivados aminopropanol como moduladores del receptor esfingosina-1-fosfato |
EP1625123A4 (en) * | 2003-05-15 | 2007-08-29 | Merck & Co Inc | 3- (2-AMINO-1-AZACYCLYL) -5-ARYL-1,2,4-OXADIAZOLE AS S1P RECEPTOR AGONISTS |
US20070043014A1 (en) * | 2003-10-01 | 2007-02-22 | Merck & Co., Inc. | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
CA2547198A1 (en) * | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
AU2005299851B2 (en) | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
ES2395929T3 (es) | 2005-02-25 | 2013-02-18 | Ono Pharmaceutical Co., Ltd. | Compuestos de indol para tratar trastornos respiratorios |
KR20070116645A (ko) * | 2005-03-23 | 2007-12-10 | 액테리온 파마슈티칼 리미티드 | 스핑고신-1-포스페이트-1 수용체 길항제로서의 신규한티오펜 유도체 |
TW200642683A (en) * | 2005-04-22 | 2006-12-16 | Sankyo Co | Heterocyclic compound |
US20080306124A1 (en) * | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
KR20080047410A (ko) * | 2005-08-23 | 2008-05-28 | 아이알엠 엘엘씨 | 면역억제제 화합물 및 조성물 |
GB0601744D0 (en) * | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
BRPI0709866B8 (pt) * | 2006-04-03 | 2021-05-25 | Astellas Pharma Inc | compostos héteros e composição farmacêutica compreendendo ditos compostos |
JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
-
2008
- 2008-04-17 CA CA002684385A patent/CA2684385A1/en not_active Abandoned
- 2008-04-17 AU AU2008240773A patent/AU2008240773B2/en not_active Expired - Fee Related
- 2008-04-17 PE PE2008000672A patent/PE20090150A1/es not_active Application Discontinuation
- 2008-04-17 MX MX2009011155A patent/MX2009011155A/es active IP Right Grant
- 2008-04-17 WO PCT/EP2008/054647 patent/WO2008128951A1/en active Application Filing
- 2008-04-17 EA EA200970967A patent/EA016443B1/ru not_active IP Right Cessation
- 2008-04-17 AR ARP080101584A patent/AR066095A1/es not_active Application Discontinuation
- 2008-04-17 AT AT08736315T patent/ATE500252T1/de not_active IP Right Cessation
- 2008-04-17 NZ NZ579595A patent/NZ579595A/en not_active IP Right Cessation
- 2008-04-17 JP JP2010503494A patent/JP5313229B2/ja not_active Expired - Fee Related
- 2008-04-17 TW TW097113880A patent/TWI408137B/zh not_active IP Right Cessation
- 2008-04-17 MY MYPI20094368A patent/MY146606A/en unknown
- 2008-04-17 US US12/596,488 patent/US8324254B2/en not_active Expired - Fee Related
- 2008-04-17 JO JO2008183A patent/JO2686B1/en active
- 2008-04-17 CL CL200801099A patent/CL2008001099A1/es unknown
- 2008-04-17 KR KR1020097021613A patent/KR20090130062A/ko not_active Application Discontinuation
- 2008-04-17 EP EP08736315A patent/EP2137181B1/en not_active Not-in-force
- 2008-04-17 BR BRPI0809472-1A patent/BRPI0809472A2/pt not_active IP Right Cessation
- 2008-04-17 DE DE602008005285T patent/DE602008005285D1/de active Active
-
2009
- 2009-09-10 IL IL200870A patent/IL200870A/en not_active IP Right Cessation
- 2009-10-08 DO DO2009000237A patent/DOP2009000237A/es unknown
- 2009-10-15 MA MA32280A patent/MA31311B1/fr unknown
- 2009-10-16 CO CO09115828A patent/CO6321136A2/es active IP Right Grant
- 2009-11-19 CR CR11119A patent/CR11119A/es not_active Application Discontinuation
-
2010
- 2010-04-29 HK HK10104250.5A patent/HK1138001A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE500252T1 (de) | 2011-03-15 |
PE20090150A1 (es) | 2009-05-08 |
JP5313229B2 (ja) | 2013-10-09 |
JP2010524886A (ja) | 2010-07-22 |
EP2137181B1 (en) | 2011-03-02 |
US8324254B2 (en) | 2012-12-04 |
MY146606A (en) | 2012-09-14 |
MA31311B1 (fr) | 2010-04-01 |
HK1138001A1 (en) | 2010-08-13 |
IL200870A0 (en) | 2010-05-17 |
CO6321136A2 (es) | 2011-09-20 |
US20100113528A1 (en) | 2010-05-06 |
IL200870A (en) | 2013-08-29 |
CR11119A (es) | 2010-01-18 |
KR20090130062A (ko) | 2009-12-17 |
EA200970967A1 (ru) | 2010-02-26 |
EP2137181A1 (en) | 2009-12-30 |
CL2008001099A1 (es) | 2008-10-24 |
NZ579595A (en) | 2012-06-29 |
DOP2009000237A (es) | 2010-05-31 |
DE602008005285D1 (de) | 2011-04-14 |
BRPI0809472A2 (pt) | 2014-09-09 |
TWI408137B (zh) | 2013-09-11 |
AU2008240773A1 (en) | 2008-10-30 |
AU2008240773B2 (en) | 2013-10-03 |
JO2686B1 (en) | 2013-03-03 |
CA2684385A1 (en) | 2008-10-30 |
TW200911794A (en) | 2009-03-16 |
MX2009011155A (es) | 2009-10-30 |
WO2008128951A1 (en) | 2008-10-30 |
EA016443B1 (ru) | 2012-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066095A1 (es) | Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla | |
AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
AR064452A1 (es) | Derivados de 1,2,4 oxadiazol-indol,composiciones farmaceuticas que los comprenden y usos en trastornos asociados a receptores s1p1. | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
NI201500030A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
AR067058A1 (es) | Oxazolidinonas sustituidas y su uso para preparar medicamentos | |
UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
CO6351793A2 (es) | \"derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis | |
UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
UY35242A (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR087668A1 (es) | Derivados de oxazina y su uso en el tratamiento de enfermedades | |
CL2011001224A1 (es) | Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c. | |
AR057906A1 (es) | Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta. | |
UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
AR072224A1 (es) | Derivados de pirimidona sustituidos | |
AR072227A1 (es) | Derivados de triazinona sustituidos | |
AR044078A1 (es) | Dihidroquinazolinas sustituidas | |
AR054508A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla | |
CL2011001413A1 (es) | Compuestos derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para la prevencion o el tratamiento de una infeccion bacteriana. | |
AR062737A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento | |
ECSP088257A (es) | Derivados de amida | |
AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |